Botulism

DEADLINE REMINDER: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Evolus, Inc. (EOLS)

Retrieved on: 
Thursday, October 29, 2020
Legal, Professional services, Drugs, Toxins, Botulinum toxin, Botulism, Neurotoxins, ITC, Toxicology

Investors suffering losses on their investments Evolus are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .

Key Points: 
  • Investors suffering losses on their investments Evolus are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • On July 6, 2020, the U.S. International Trade Commission (ITC) issued its Final Initial Determination in a case alleging that Evolus stole certain trade secrets to develop Jeuveau.
  • The ITC Judge found that Evolus misused the botulinum toxin strain as well as the manufacturing processes that led to its development and manufacture.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Shareholder Alert: Robbins LLP Announces that Evolus, Inc. (EOLS) is Being Sued for Misleading Shareholders

Retrieved on: 
Thursday, October 22, 2020
Legal, Professional services, Drugs, Botulism, Plastic surgery, Toxins, Botulinum toxin, Neurotoxins, Medical specialties

Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States.

Key Points: 
  • Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States.
  • Evolus' sole product is Jeuveau, a purified botulinum toxin indicated for the temporary improvement in the appearance of moderate to severe frown lines in adults, which competes with Botox.
  • As a result, the ITC Judge recommended a ten-year long ban on Evolus' ability to import and sell Jeuveau in the United States.
  • On this news, Evolus' stock dropped 37% in two days to close at $3.35 on July 8, 2020.

The Law Offices of Frank R. Cruz Announces Investigation of Evolus, Inc. (EOLS) on Behalf of Investors

Retrieved on: 
Thursday, October 22, 2020
Legal, Professional services, Drugs, Toxins, Botulinum toxin, Botulism, Neurotoxins, Lluís Companys, Toxicology

The Law Offices of Frank R. Cruz announces an investigation of Evolus, Inc. (Evolus or the Company) (NASDAQ: EOLS ) on behalf of investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of Evolus, Inc. (Evolus or the Company) (NASDAQ: EOLS ) on behalf of investors concerning the Companys possible violations of federal securities laws.
  • On July 6, 2020, the U.S. International Trade Commission (ITC) issued its Final Initial Determination in a case alleging that Evolus stole certain trade secrets to develop Jeuveau.
  • The ITC Judge found that Evolus misused the botulinum toxin strain as well as the manufacturing processes that led to its development and manufacture.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Evolus, Inc. (EOLS) on Behalf of Investors

Retrieved on: 
Thursday, October 22, 2020
Legal, Professional services, Drugs, Toxins, Botulinum toxin, Botulism, Neurotoxins, Lluís Companys, Toxicology

Law Offices of Howard G. Smith announces an investigation on behalf of Evolus, Inc. (Evolus or the Company) (NASDAQ: EOLS ) investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of Evolus, Inc. (Evolus or the Company) (NASDAQ: EOLS ) investors concerning the Companys possible violations of federal securities laws.
  • On July 6, 2020, the U.S. International Trade Commission (ITC) issued its Final Initial Determination in a case alleging that Evolus stole certain trade secrets to develop Jeuveau.
  • The ITC Judge found that Evolus misused the botulinum toxin strain as well as the manufacturing processes that led to its development and manufacture.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SHAREHOLDER ALERT: Lowey Dannenberg Files Securities Class Action Lawsuit Against Evolus, Inc. (Newport Beach, California) on Behalf of Investors Who Acquired Shares from February 1, 2019 to July 6, 2020, and Encourages Investors to Inquire About the Lead

Retrieved on: 
Friday, October 16, 2020
Drugs, Botulism, Toxins, Companies, Botulinum toxin, Neurotoxins, Allergan, Draft:List Biological Laboratories

Headquartered in Newport Beach, California, Evolus is a medical aesthetics company that develops, produces, and markets clinical neurotoxins for the treatment of aesthetic concerns.

Key Points: 
  • Headquartered in Newport Beach, California, Evolus is a medical aesthetics company that develops, produces, and markets clinical neurotoxins for the treatment of aesthetic concerns.
  • Evolus sole product is Jeuveau, a purified botulinum toxin used to improve the appearance of moderate to severe frown lines.
  • Evolus directly competes with Botox, which is manufactured by Allergan plc and Allergan Inc. (collectively, Allergan) and distributed by Medytox Inc. (Medytox).
  • Any member of the proposed Class may move to serve as the Lead Plaintiff through counsel of their choice.

Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia

Retrieved on: 
Wednesday, October 14, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Drugs, Branches of biology, Chemical compounds, Botulinum toxin, Botulism, Neurotoxins, Toxins, Upadacitinib, Hydroxyprogesterone caproate, Cervical Dystonia, Revance Therapeutics, Inc.

SAFETY RESULTS: In both dose groups, DaxibotulinumtoxinA for Injection appeared to be generally safe and well-tolerated through Week 36.

Key Points: 
  • SAFETY RESULTS: In both dose groups, DaxibotulinumtoxinA for Injection appeared to be generally safe and well-tolerated through Week 36.
  • In 2017, the U.S. Food and Drug Administration (FDA) granted orphan drug designation for DaxibotulinumtoxinA for Injection to treat cervical dystonia, which provides certain developmental and financial benefits to trial sponsors.
  • Randomized Trial (ASPEN-1): Patients were randomized to a single treatment of either 125 Unit or 250 Unit dose of DaxibotulinumtoxinA for Injection, or placebo.
  • Primary endpoints of the trial are safety and immunogenicity after multiple cycles of treatment with DaxibotulinumtoxinA for Injection.

China Botulinum Toxin Type A Investigation Market Report, 2020-2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 12, 2020
Pharmaceutical, Health, Other Health, Botulism, Drugs, Toxins, Botulinum toxin, Neurotoxins, Medical specialties, Clostridium botulinum, Draft:List Biological Laboratories

In addition to the imported Botulinum Toxin Type A (trade name: Botox) produced by Allergan, the Botulinum Toxin Type A products in China also include Botulinum Toxin Type A (trade name: Hengli) developed by Lanzhou Institute of Biological Products Co., Ltd.

Key Points: 
  • In addition to the imported Botulinum Toxin Type A (trade name: Botox) produced by Allergan, the Botulinum Toxin Type A products in China also include Botulinum Toxin Type A (trade name: Hengli) developed by Lanzhou Institute of Biological Products Co., Ltd.
  • According to this market research, Botulinum Toxin Type A has been growing rapidly since it entered China.
  • As the demand for Botulinum Toxin Type A is expanding, some medical institutions and beauty salons have begun to inject Botulinum Toxin Type A smuggled from South Korea, France, Germany, etc.
  • 2 Sales of Botulinum Toxin Type A in China, 2015-2019
    2.3 Sales of Botulinum Toxin Type A by Dosage Form in China, 2015-2019
    3 Analysis on Major Manufacturers of Botulinum Toxin Type A in China, 2015-2019
    3.3 Lanzhou Institute of Biological Products Co., Ltd.
    4 Prices of Botulinum Toxin Type A in China, 2019-2020
    4.1 Average price of Botulinum Toxin Type A in China, 2019-2020
    4.3 Average price of Lanzhou Institute of Biological Products Co., Ltd.'s Botulinum Toxin Type A (Hengli)
    5 Prospects of China's Botulinum Toxin Type A Market, 2020-2024
    View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005665/en/

Revance to Present Three New Abstracts Evaluating DaxibotulinumtoxinA for Injection and Two ePosters Evaluating the RHA® Collection During the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting

Retrieved on: 
Tuesday, October 6, 2020
Biotechnology, Pharmaceutical, Health, Drugs, Plastic surgery, Toxins, Botulinum toxin, Botulism, Neurotoxins, Medical specialties

Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection.

Key Points: 
  • Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection.
  • Revance Therapeutics and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
    RHA resilient hyaluronic acid and RHA are trademarks of TEOXANE SA.
  • A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 Study.
  • Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines.

Croma Establishes New Joint Venture in China

Retrieved on: 
Tuesday, September 15, 2020
Biotechnology, Pharmaceutical, Medical Supplies, General Health, Health, Cosmetics, Retail, Other Health, Drugs, Toxins, Botulinum toxin, Botulism, Neurotoxins, Lanzhou, Croma, 2-hydroxymuconate tautomerase, Croma-Pharma GmbH - leading experts in Hyaluronic Acid, CNBG

CNBG and Croma entered a far reaching, long-term cooperation combining each partners assets in a newly founded Joint Venture company to market Cromas aesthetic products in China and Hong Kong.

Key Points: 
  • CNBG and Croma entered a far reaching, long-term cooperation combining each partners assets in a newly founded Joint Venture company to market Cromas aesthetic products in China and Hong Kong.
  • The joint company aims to become a comprehensive supplier of minimally invasive aesthetic products in China, making effective use of the existing field force of Lanzhou.
  • Xiangrong Li, Vice-president of CNBG said: CNBG, via its affiliate Lanzhou, has been very successful for years with its botulinum toxin in China.
  • Andreas Prinz, CCO and Co-Owner of Croma: "Croma incorporates more than 40 years of experience in R&D of viscoelastic products.